386.34

0.17% +0.64

Medpace Holdings Inc (MEDP)

Overview News Price History Option Chain Financials Discussions Forecast

Medpace Holdings Inc stock is currently priced at $386.34, with a 24-hour trading volume of 276.08K. It has seen a +0.17% increased in the last 24 hours and a -0.52% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $384.9 pivot point. If it approaches the $390.7 resistance level, significant changes may occur.

Previous Close:

$385.70

Open:

$387.92

24h Volume:

276.08K

Market Cap:

$11.97B

Revenue:

$1.96B

Net Income/Loss:

$312.51M

P/E Ratio:

45.24

EPS:

8.54

Net Cash Flow:

$473.34M

1W Performance:

-1.08%

1M Performance:

-0.52%

6M Performance:

+42.71%

1Y Performance:

+86.66%

1D Range:

$381.03

$392.93

52W Range:

$202.02

$421.00

Medpace Holdings Inc Stock (MEDP) Company Profile

Name

Medpace Holdings Inc

Sector

Healthcare (1198)

Industry

Diagnostics & Research (65)

Phone

513-579-9911

Address

5375 Medpace Way, Cincinnati, OH

Employee

2,800

Twitter

@WorkatMedpace

Next Earnings Date

2024-05-17

Latest SEC Filings

MEDP's Discussions on Twitter

Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Upgrade	UBS	Neutral → Buy
Oct-24-23	Upgrade	Robert W. Baird	Neutral → Outperform
May-08-23	Upgrade	Guggenheim	Neutral → Buy
Oct-27-22	Upgrade	UBS	Sell → Neutral
Sep-07-22	Initiated	UBS	Sell
May-24-22	Initiated	Guggenheim	Neutral
Aug-05-21	Resumed	Credit Suisse	Outperform
Oct-02-20	Upgrade	Truist	Hold → Buy
Jun-08-20	Upgrade	Robert W. Baird	Underperform → Neutral
May-13-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Apr-30-20	Upgrade	SunTrust	Sell → Hold
Apr-20-20	Downgrade	Robert W. Baird	Neutral → Underperform
Mar-17-20	Downgrade	SunTrust	Hold → Sell
Jan-27-20	Downgrade	SunTrust	Buy → Hold
Oct-31-18	Upgrade	SunTrust	Hold → Buy
Sep-17-18	Initiated	SunTrust	Hold
Jul-31-18	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-17	Downgrade	William Blair	Outperform → Mkt Perform
Sep-29-17	Initiated	Raymond James	Mkt Perform
Jul-10-17	Downgrade	KeyBanc Capital Mkts	Overweight → Sector Weight

View All

Medpace Holdings Inc Stock (MEDP) Latest News

Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Defense World

Evoke Wealth LLC Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP) - MarketBeat

MarketBeat

Medpace Holdings Inc Stock (MEDP) Financials Data

Medpace Holdings Inc (MEDP) Revenue 2024

MEDP reported a revenue (TTM) of $1.96 billion for the quarter ending March 31, 2024, a +25.57% rise year-over-year.

Medpace Holdings Inc (MEDP) Net Income 2024

MEDP net income (TTM) was $312.51 million for the quarter ending March 31, 2024, a +21.62% increase year-over-year.

Medpace Holdings Inc (MEDP) Cash Flow 2024

MEDP recorded a free cash flow (TTM) of $473.34 million for the quarter ending March 31, 2024, a +23.03% increase year-over-year.

Medpace Holdings Inc (MEDP) Earnings per Share 2024

MEDP earnings per share (TTM) was $9.81 for the quarter ending March 31, 2024, a +24.18% growth year-over-year.

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.